Gene therapy for ischemic cardiovascular disease:: Somes lessons learned from the first clinical trials

被引：59

作者：

Ylä-Herttuala, S

Markkanen, JE

Rissanen, TT

机构：

[1] Univ Kuopio, AI Virtanen Inst, FIN-70211 Kuopio, Finland

[2] Univ Kuopio, Dept Med, FIN-70211 Kuopio, Finland

来源：

TRENDS IN CARDIOVASCULAR MEDICINE | 2004年 / 14卷 / 08期

关键词：

D O I：

10.1016/j.tcm.2004.09.001

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Stimulation of angiogenesis, arteriogenesis, and lymphangiogenesis (i.e., therapeutic vascular growth) is a new concept for the treatment of ischemic cardiovascular diseases. A wealth of information is already available about the mechanisms and mediators of angiogenesis and arteriogenesis, which has led to the first randomized, controlled, phase II/III trials with recombinant growth factors or their genes. Even though end points predefined in the study protocols have been positive in several trials, it is still evident that the trials have not produced any clearly meaningful clinical benefits for the patients. This review addresses same questions and concepts related to the gene therapy-based applications of therapeutic vascular growth. (C) 2004, Elsevier Inc.

引用

页码：295 / 300

页数：6

共 26 条

[1] Angiogenic responses of vascular endothelial growth factors in periadventitial tissue [J].

Bhardwaj, S ;

Roy, H ;

Gruchala, M ;

Viita, H ;

Kholova, I ;

Kokina, I ;

Achen, MG ;

Stacker, SA ;

Hedman, M ;

Alitalo, K ;

Ylä-Herttuala, S .

HUMAN GENE THERAPY, 2003, 14 (15) :1451-1462

[2]

Champion HC, 2002, CIRCULATION, V106, P25

[3] Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis [J].

Dor, Y ;

Porat, R ;

Keshet, E .

AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 2001, 280 (06) :C1367-C1374

[4] Angiogenic GENe Therapy (AGENT) trial in patients with stable angina pectoris [J].

Grines, CL ;

Watkins, MW ;

Helmer, G ;

Penny, W ;

Brinker, J ;

Marmur, JD ;

West, A ;

Rade, JJ ;

Marrott, P ;

Hammond, HK ;

Engler, RL .

CIRCULATION, 2002, 105 (11) :1291-1297

[5] Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia -: Phase II results of the Kuopio Angiogenesis Trial (KAT) [J].

Hedman, M ;

Hartikainen, J ;

Syvänne, M ;

Stjernvall, J ;

Hedman, A ;

Kivelä, A ;

Vanninen, E ;

Mussalo, H ;

Kauppila, E ;

Simula, S ;

Närvänen, O ;

Rantala, A ;

Peuhkurinen, K ;

Nieminen, MS ;

Laakso, M ;

Ylä-Herttuala, S .

CIRCULATION, 2003, 107 (21) :2677-2683

[6] Vascular endothelial growth factor in ischemia for vascular angiogenesis [J].

Henry, TD ;

Annex, BH ;

McKendall, GR ;

Azrin, MA ;

Lopez, JJ ;

Giordano, FJ ;

Shah, PK ;

Willerson, JT ;

Benza, RL ;

Berman, DS ;

Gibson, CM ;

Bajamonde, A ;

Rundle, AC ;

Fine, J ;

McCluskey, ER .

CIRCULATION, 2003, 107 (10) :1359-1365

[7]

KASTRUP J, 2003, J AM COLL CARDIOL, V41, P1603

[8] Adenovirus-mediated gene transfer to lower limb artery of patients with chronic critical leg ischemia [J].

Laitinen, M ;

Mäkinen, K ;

Manninen, H ;

Matsi, P ;

Kossila, M ;

Agrawal, RS ;

Pakkanen, T ;

Luoma, JS ;

Viita, H ;

Hartikainen, J ;

Alhava, E ;

Laakso, M ;

Ylä-Herttuala, S .

HUMAN GENE THERAPY, 1998, 9 (10) :1481-1486

[9] VEGF gene transfer reduces intimal thickening via increased production of nitric oxide in carotid arteries [J].

Laitinen, M ;

Zachary, I ;

Breier, G ;

Pakkanen, T ;

Hakkinen, T ;

Luoma, J ;

Abedi, H ;

Risau, W ;

Soma, M ;

Laakso, M ;

Martin, JF ;

YlaHerttuala, S .

HUMAN GENE THERAPY, 1997, 8 (15) :1737-1744

[10] Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial [J].

Lederman, RJ ;

Mendelsohn, FO ;

Anderson, RD ;

Saucedo, JF ;

Tenaglia, AN ;

Hermiller, JB ;

Hillegass, WB ;

Rocha-Singh, K ;

Moon, TE ;

Whitehouse, MJ ;

Annex, BH .

LANCET, 2002, 359 (9323) :2053-2058

← 1 2 3 →